VistaGen Therapeutics, Inc.
VTGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | -$0 | $0 |
| % Growth | 5.7% | 1,726.7% | -106.4% | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 100% | 30.7% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -7,454.3% | -6,117.2% | 95,526.7% | -6,392.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -7,526% | -6,186.5% | 90,900% | -6,020.9% |
| EPS Diluted | -0.54 | -0.47 | -0.44 | -0.46 |
| % Growth | -14.9% | -6.8% | 4.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |